These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 26262839)
21. Carbohydrate-based vaccines for oncotherapy. Wei MM; Wang YS; Ye XS Med Res Rev; 2018 May; 38(3):1003-1026. PubMed ID: 29512174 [TBL] [Abstract][Full Text] [Related]
22. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894 [TBL] [Abstract][Full Text] [Related]
23. A fully synthetic immunogen carrying a carcinoma-associated carbohydrate for active specific immunotherapy. Lo-Man R; Bay S; Vichier-Guerre S; Dériaud E; Cantacuzène D; Leclerc C Cancer Res; 1999 Apr; 59(7):1520-4. PubMed ID: 10197623 [TBL] [Abstract][Full Text] [Related]
24. The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity. Laubreton D; Bay S; Sedlik C; Artaud C; Ganneau C; Dériaud E; Viel S; Puaux AL; Amigorena S; Gérard C; Lo-Man R; Leclerc C Cancer Immunol Immunother; 2016 Mar; 65(3):315-25. PubMed ID: 26847142 [TBL] [Abstract][Full Text] [Related]
26. Recent development in carbohydrate-based cancer vaccines. Guo Z; Wang Q Curr Opin Chem Biol; 2009 Dec; 13(5-6):608-17. PubMed ID: 19766052 [TBL] [Abstract][Full Text] [Related]
27. Enhancement of the immunogenicity of synthetic carbohydrate vaccines by chemical modifications of STn antigen. Yang F; Zheng XJ; Huo CX; Wang Y; Zhang Y; Ye XS ACS Chem Biol; 2011 Mar; 6(3):252-9. PubMed ID: 21121644 [TBL] [Abstract][Full Text] [Related]
28. Synthesis and immunological evaluation of an antitumor neoglycopeptide vaccine bearing a novel homoserine Tn antigen. Vichier-Guerre S; Lo-Man R; Huteau V; Dériaud E; Leclerc C; Bay S Bioorg Med Chem Lett; 2004 Jul; 14(13):3567-70. PubMed ID: 15177475 [TBL] [Abstract][Full Text] [Related]
29. Improving the antigenicity of sTn antigen by modification of its sialic acid residue for development of glycoconjugate cancer vaccines. Wu J; Guo Z Bioconjug Chem; 2006; 17(6):1537-44. PubMed ID: 17105234 [TBL] [Abstract][Full Text] [Related]
30. Synthesis of selected LeY and KH-1 analogues: a medicinal chemistry approach to vaccine optimization. Spassova MK; Bornmann WG; Ragupathi G; Sukenick G; Livingston PO; Danishefsky SJ J Org Chem; 2005 Apr; 70(9):3383-95. PubMed ID: 15844973 [TBL] [Abstract][Full Text] [Related]
31. Synthetic and immunological studies of N-acyl modified S-linked STn derivatives as anticancer vaccine candidates. Huo CX; Zheng XJ; Xiao A; Liu CC; Sun S; Lv Z; Ye XS Org Biomol Chem; 2015 Mar; 13(12):3677-90. PubMed ID: 25679360 [TBL] [Abstract][Full Text] [Related]
32. Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma. Monzavi-Karbassi B; Hennings LJ; Artaud C; Liu T; Jousheghany F; Pashov A; Murali R; Hutchins LF; Kieber-Emmons T Vaccine; 2007 Apr; 25(16):3022-31. PubMed ID: 17303294 [TBL] [Abstract][Full Text] [Related]
34. [Preliminary observation on antitumor effect of HPV58 composite DNA vaccine]. Wang H; Yu JY; Li L Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):523-7. PubMed ID: 24284225 [TBL] [Abstract][Full Text] [Related]
35. Recent Advance in Tumor-associated Carbohydrate Antigens (TACAs)-based Antitumor Vaccines. Feng D; Shaikh AS; Wang F ACS Chem Biol; 2016 Apr; 11(4):850-63. PubMed ID: 26895482 [TBL] [Abstract][Full Text] [Related]
36. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311 [TBL] [Abstract][Full Text] [Related]
37. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Saha A; Chatterjee SK Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858 [TBL] [Abstract][Full Text] [Related]